Stockwatch: Cardinal rule adherence – HALO slips but Shire shines
This article was originally published in Scrip
A cardinal rule in pharmaceutical drug development is that you never put the sales of an existing product at risk for a second generation product that may never exist. This is because you don't have to do much risk-adjustment for the sales of a product already on the market - it is real cash flow. However, because there are so many unknowns with a product early in development, you should significantly risk-adjust those cash flows, and not sacrifice the real ones, for the possible ones. Sure, you might get cannibalisation with both first and second generation products end up on the market, but that should be the only harm that one product does to another.
You may also be interested in...
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.
It is one thing to aspire to build a rival to another company’s banner therapeutic franchise, but quite another to start from the ground up, especially when your form in that area is mixed.